- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00383890
A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine Used for Sedation During Elective Awake Fiberoptic Intubation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An awake fiberoptic intubation is indicated for any patient with an anticipated difficult airway because of their anatomy, airway trauma, morbid obesity, or unstable cervical spine injuries. An awake fiberoptic intubation in a non-sedated patient can be extremely stimulating, uncomfortable, and unpleasant. The clinician must focus on maintaining spontaneous breathing, hemodynamic stability, and the patient's comfort. The term "awake" fiberoptic intubation is used to distinguish this procedure from fiberoptic intubations performed under general anesthesia. Although patients may be sedated for "awake" fiberoptic intubation, they need to be responsive and capable of maintaining their own airway without assistance. Vital components of a successful awake fiberoptic intubation include an anesthesiologist experienced in this technique, adequate topicalization of the airway, and a sedated yet cooperative subject.
Benzodiazepines, combined with opioid, are commonly used for anxiolysis and/or analgesia during awake fiberoptic intubations.
Dexmedetomidine has sympatholytic, sedative, analgesic, and anxiolytic effects that attenuate the catecholamine response to perioperative stress. Dexmedetomidine sedates patients by decreasing sympathetic activity and the level of arousal. Further more, dexmedetomidine has been found to facilitate a decrease in salivary secretion, a desirable effect during fiberoptic intubations.
An estimated 100 subjects (50 DEX, 50 PBO) scheduled for an elective awake fiberoptic intubation because of a potentially difficult airway will be randomized prior to intubation at approximately 18 investigative sites.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
California
-
Loma Linda, California, United States, 92354
- Loma Linda University Medical Center
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Jackson Memorial Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois Medical Center at Chicago
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Rochester
-
-
New York
-
New York, New York, United States, 10016
- New York University Medical Center
-
New York, New York, United States, 10029
- The Mount Sinai School of Medicine
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic Foundation
-
Columbus, Ohio, United States, 43210-1228
- The Ohio State University Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103-6296
- LeHigh Valley Hospital
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, United States, 75216
- VA North Texas Health Care System
-
Houston, Texas, United States, 77030
- The University of Texas
-
Houston, Texas, United States, 77030
- The University of Texas Medical School at Houston
-
Temple, Texas, United States, 76508
- Scott and White Memorial Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53295
- VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (≥18 years of age);
- American Society of Anesthesiologists (ASA) score I - IV inclusive;
Male or female. If female, subject is non-lactating and is either:
- Not of childbearing potential, defined as post-menopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.
- Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of birth control: oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse.
Requiring awake fiberoptic (oral or nasal) intubation because of anticipated difficult airway. Subjects must meet at least one of the criteria listed below:
Criteria for Assessing Difficult Airways
i. History of difficult intubation
ii. Anticipated difficult airway
- Prominent protruding teeth
- Small mouth opening
- Narrow mandible
- Micrognathia
- Macroglossia
- Short, muscular neck
- Very long neck
- Limited neck extension
- Congenital airway anomalies
- Obesity
- Known airway pathology
- Known airway malignancy
- Upper airway obstruction
iii. Trauma
- Face
- Upper airway
- Cervical spine
iv. Anticipated difficult mask ventilation
v. Severe risk of aspiration
vi. Respiratory failure
vii. Severe hemodynamic instability
- Subject (or subject's legally authorized representative) must voluntarily sign and date the informed consent.
Exclusion Criteria:
- Previous exposure to any experimental drug within 30 days prior to study drug administration;
- Central nervous system (CNS) disease with an anticipated increased intracranial pressure or cerebrospinal fluid (CSF) leak;
- Uncontrolled seizure disorder and/or known psychiatric illness that could confound a normal response to sedative treatment;
- Presence of acute alcohol intoxication;
- Current (within 14 days of study entry) treatment with an α2-agonist or antagonist;
- Subject for whom benzodiazepines, dexmedetomidine or other α2-agonists are contraindicated;
- Subject received an IV or oral (PO) opioid within one hour or intramuscularly within four hours of the start of study drug administration;
- Subject has acute unstable angina, laboratory confirmed acute myocardial infarction within the past 6 weeks, heart rate <50 bpm, systolic blood pressure (SBP) <90 mmHg, or complete heart block unless they have a pacemaker.
- Subject has elevated serum glutamic pyruvate aminotransferase/alanine transaminase (SGPT/ALT) and/or Serum glutamic oxaloacetic transaminase/ aspartate aminotransferase (SGOT/AST) values of ≥2 times the upper limit of normal (ULN).
- Subject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Dexmedetomidine
Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min
|
|
|
Placebo Comparator: Placebo (PBO)
Placebo load for 10 min and Placebo maintenance for 15 min
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The percentage of subjects requiring rescue midazolam to achieve and/or maintain proper sedation levels throughout the study drug infusion
Time Frame: At baseline and 15 minutes after starting study drug (prior to topicalization), and every 3 minutes thereafter throughout study drug infusion, at the end of topicalization, and prior to administration of any rescue medication.
|
Sedation levels (Ramsay Sedation Scale [RSS] score ≥2 [Patient is cooperative, oriented and tranquil])
|
At baseline and 15 minutes after starting study drug (prior to topicalization), and every 3 minutes thereafter throughout study drug infusion, at the end of topicalization, and prior to administration of any rescue medication.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total dose of rescue midazolam required to achieve and/or maintain target sedation levels
Time Frame: During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).
|
During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).
|
|
Percentage of subjects requiring additional rescue medications other than midazolam to achieve and/or maintain target sedation levels
Time Frame: During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).
|
During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).
|
|
Anesthesiologist assessment of ease of subject care
Time Frame: Immediately following discontinuation of study drug, prior to the scheduled surgery/procedure (Approximately 24 hours).
|
Immediately following discontinuation of study drug, prior to the scheduled surgery/procedure (Approximately 24 hours).
|
|
Subject recall and satisfaction assessed 24 hours post study drug
Time Frame: At the end of the 24-Hour Follow-Up Period
|
At the end of the 24-Hour Follow-Up Period
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- 2005-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.